| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.12.8.886 |
| P953 | full work available at URL | https://www.ahajournals.org/doi/pdf/10.1161/01.ATV.12.8.886 |
| P698 | PubMed publication ID | 1637786 |
| P2093 | author name string | M. C. Phillips | |
| J. P. Segrest | |||
| G. M. Anantharamaiah | |||
| K. B. Gupta | |||
| D. W. Garber | |||
| J. B. Hazelrig | |||
| J. Ibdah | |||
| Y. V. Venkatachalapathi | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cardiology and cardiovascular medicine | Q96320350 |
| P304 | page(s) | 886-894 | |
| P577 | publication date | 1992-08-01 | |
| P1433 | published in | Arteriosclerosis and thrombosis : a journal of vascular biology | Q27709770 |
| P1476 | title | Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties | |
| P478 | volume | 12 |
| Q37297837 | A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. |
| Q35082742 | An amphipathic alpha-helical peptide from apolipoprotein A1 stabilizes protein polymer vesicles |
| Q37299899 | An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide |
| Q34238630 | Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review |
| Q38293513 | ApoA-I mimetics |
| Q35172781 | Apolipoprotein A-I mimetic peptide L-4F prevents myocardial and coronary dysfunction in diabetic mice |
| Q37334578 | Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties |
| Q34927488 | Biological properties of apolipoprotein a-I mimetic peptides |
| Q38297747 | Carboxyl-terminal domain truncation alters apolipoprotein A-I in vivo catabolism |
| Q44474822 | Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice |
| Q35212906 | Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma |
| Q27691344 | HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders |
| Q37354180 | Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits. In vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner |
| Q34955938 | Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally |
| Q35203793 | Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment |
| Q37308178 | Multiple indications for anti-inflammatory apolipoprotein mimetic peptides. |
| Q28546760 | Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of preβ-1 HDL In Vitro |
| Q37553765 | Structure and function of HDL mimetics |
| Q34191172 | Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol |
| Q38767234 | The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease |
| Q34053131 | The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats |
| Q34503423 | Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. |
Search more.